Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-elemene with EGFR-TKI in Advanced EGFR-TKI-resistant NSCLC
NCT03123484Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Elemene in non-small cell lung cancer (NSCLC) (2 arms), sponsored by China Medical University. Primary endpoint: Progression-Free Survival ratio at 12 weeks. Status: unknown.
02
Drugs
Elemene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03123484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123484.